Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.37 |
| ▸ | CHRNG | P07510 | 1/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351393 | 0.82 | AKR1C1 (0.55) | LMNACYP2C19HSD11B1CYP3A4CYP2D6 | |
| SCHEMBL10535071 | 0.82 | AKR1C1 (0.61) | LMNAHSD11B1AKR1C1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16897539 | 0.81 | LMNA (0.60) | LMNACYP2C19HSD11B1CYP3A4CYP2D6 | |
| SCHEMBL12988917 | 0.81 | AKR1C1 (0.41) | AKR1C1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL10533434 | 0.81 | TET3 (0.49) | LMNAHSD11B1AKR1C1ALDH1A1KMT2A | |
| SCHEMBL26024235 | 0.80 | CYP3A4 (0.46) | LMNACYP2C19HSD11B1CYP3A4CYP2D6 | |
| SCHEMBL19438488 | 0.80 | KMT2A (0.52) | CYP2C19HSD11B1CYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3485961 | 0.78 | AKR1C1 (0.62) | LMNACYP2C19HSD11B1CYP3A4CYP2D6 | |
| SCHEMBL5790701 | 0.78 | HDAC4 (0.47) | LMNACYP2C19HSD11B1CYP3A4CYP2D6 | |
| SCHEMBL1048151 | 0.78 | AKR1C1 (0.68) | CYP2C19HSD11B1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2012009217-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | LMNA 81/4885CYP2C19 3244/4885HSD11B1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.